Spotlighting the New Generation of Cancer Specific Glyco-Mucin Targeting ADCs
- Highlighting ADCs targeting two distinct glyco-MUC1 epitopes and MUC4
- Exploring high target expression in multiple solid tumors
- Demonstrating ADC potent activity in vivo and large therapeutic window
- Evaluating the suite of glyco-Mucin epitopes for novel biparatopic ADC development